Atlas Trials

Peter Hosein, MD

3 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Peter Hosein, MD

RecordFirmDate
Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency (NCT07565155)Peter Hosein, MD2026-06-01
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) (NCT06889493)Peter Hosein, MD2025-05-19
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma (NCT05440942)Peter Hosein, MD2023-01-19

Track Peter Hosein, MD automatically

Every clearance here is in the API, with alerts when new ones post.